# OnCo record catherine-thieblemont (person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/people/catherine-thieblemont/>
  a schema:Person ;
  onco:kind "person" ;
  schema:identifier "catherine-thieblemont" ;
  schema:name "Catherine Thieblemont"@en ;
  schema:description "Led EPCORE NHL-1, the trial that established the subcutaneous bispecific epcoritamab for relapsed large B-cell lymphoma."@en ;
  schema:url <https://onco.cc/people/catherine-thieblemont/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://pubmed.ncbi.nlm.nih.gov/?term=Thieblemont%20C%5BAuthor%5D%20epcoritamab> ;
  onco:tag "lymphoma", "bispecific", "lysa" ;
  schema:jobTitle "Head of Hemato-Oncology, Hôpital Saint-Louis, Paris; Professor, Université Paris Cité" ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/bispecific-antibody/>, <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd3/> ;
  onco:institutions <https://onco.cc/institutions/aphp-nord-cancer-institute/> ;
  onco:trials <https://onco.cc/trials/epcore-nhl-1/>, <https://onco.cc/trials/epcore-dlbcl-1/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-epcore-nhl-1-epcoritamab-jco-2023/> ;
  schema:affiliation <https://onco.cc/institutions/aphp-nord-cancer-institute/> .